Quotes 5-day view Delayed Nasdaq
01/26/2023
01/27/2023
01/30/2023
01/31/2023
02/01/2023
Date
28.5(c)
29.02(c)
28.79(c)
28.64(c)
28.69(c)
Last
1 037 067
1 162 351
1 130 453
1 169 340
1 094 926
Volume
+0.56%
+1.82%
-0.79%
-0.52%
+0.17%
Change
Estimated financial data (e) (USD)
Sales 2022
1 098 M
-
-
Net income 2022
-164 M
-
-
Net cash position 2022
441 M
-
-
P/E ratio 2022
-29,3x
Yield 2022
-
Sales 2023
1 169 M
-
-
Net income 2023
-128 M
-
-
Net cash position 2023
456 M
-
-
P/E ratio 2023
-38,8x
Yield 2023
-
Capitalization
4 714 M
4 714 M
-
EV / Sales 2022
3,89x
EV / Sales 2023
3,64x
Nbr of Employees
2 211
Free-Float
95,7%
Alkermes Public Limited Company is a fully integrated biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. It has a portfolio of commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a...
All news about ALKERMES PLC
News in other languages on ALKERMES PLC
Analyst Recommendations on ALKERMES PLC
ETFs positioned on ALKERMES PLC ETFs and Trackers with Trackinsight
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ALKERMES PLC
Short Term Mid-Term Long Term Trends Bullish Bullish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
28,69 $
Average target price
32,30 $
Spread / Average Target
12,6%
Please enable JavaScript in your browser's settings to use dynamic charts.